GSK predatory abuse on hospital antibiotics in France
Conseil de la concurrence decision (80 pages in French, PDF) finding that GlaxoSmithKline has abused a dominant position though predatory pricing in 1999 and 2000 of Zinnat (an antibiotic for surgery-induced infections) and its bundling with injectable Zovirax (an antiviral drug for surgery-induced infections). The Conseil found that GSK's conduct had the anti-competitive object of slowing down the entry of generic alternatives to injectable Zinnat when its supplementary protection certificate expired in 1999.
Update, April 2008: Reversed on appeal.
For further information or advice please contact Franck Latrémolière.
Filed under Article 82, Conseil de la concurrence, France, Healthcare, Pharmaceuticals.
